Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Investor Presentation (November 2007)
19 slides from Lisata Therapeutics's investor presentation, Nov 2, 2007
Slide 1: NeoStem Investor Overview
1 NeoStem Investor Overview Robin Smith, MD, MBA CEO and Chairman of the Board (AMEX: NBS)
Slide 2: Forward Looking Statements
2 Title: FORWARD LOOKING STATEMENTS Body: This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual re
Slide 3: Agenda
3 Body: The Stem Cell Therapy Landscape Platform Business Why Should a Person Collect Today? How Our Platform Differs From Cord Blood Industry Our Broad Market Recent Events Our Revenue Model The Team Capital Structure Investor Considerations Agenda
Slide 4: Projected U.S. Stem Cell Therapy Sales
Title: Projected U.S. Stem Cell Therapy Sales 4 Source: Robert Young, RRY Publications, February 2006 $8.58 by 2016 Stem Cell Therapy: A $20 billion worldwide market by 2010 --Frost & Sullivan
Slide 5: 70+ Diseases Treated w/Stem Cells
5 Title: 70+ Diseases Treated w/Stem Cells Results for many have been quite encouraging
Slide 6: Virtually All Therapeutic Areas
6 Title: Virtually All Therapeutic Areas Body: New Therapies could be on the Market in 5-10 Years Autoimmune Diabetes/Metabolic Cardiovascular Orthopedic (Gp:) Fracture (Gp:) 2 Months Post BMSC Over 750 Adult Stem Cell Clinical Trials Over 240 Specific to Autologous Use
Slide 7: Cardiovascular Clinical Trials
7 Title: 131 Cardiovascular Clinical Trials Reference. clinicaltrials.gov One Indication Only!
Slide 8: Platform Business
8 Title: Platform Business Body: NeoStem has a safe and non invasive way for adults to have their stem cells collected today and stored for future use. Our platform will allow doctors and patients ready access to their cells as the therapies become available in the future.
Slide 9: Why Should a Person Collect Today
9 Title: Why Should a Person Collect Today Body: Finding an ostensively “matching” donor is very difficult People are dying on the “wait list” (4 mo. avg.) Rejection-Graft vs. Host Disease (40% chance even if “perfect” match) Risk of transmission of communicable disease Possible reluctance to collec
Slide 10: Our Platform Differs From Cord Blood Industry
10 Title: Our Platform Differs From Cord Blood Industry
Slide 11: A Broad Target Market
11 Title: A Broad Target Market Body: People with family history of disease; Patients in a pre-disease or early-disease states; Parents who have banked their children’s cord blood; First responders military personnel Policemen, firemen; EMS Industry (workers facing exposure to radiation/chemicals) B
Slide 12: Recent Events
12 Title: Recent Events Body: Closed on $6,350,000 Listed on the American Stock Exchange Launched Las Vegas Signed multi-center agreement initially to expand in Midwest with Stem Collect, LLC founded by James Doty, MD, former CEO of $1B Nasdaq Medical Device Co. Accuray Signed agreement for New York
Slide 13: Our Revenue Model
13 Title: Our Revenue ModelBody: Current: Collection Center FeesCollection from patientsProcessing patient cellsStorage (recurring revenue)Potential:Utilization feesSupplier of cellsCollection fees for trialsGovernment/military contractsSBIR grantsLicensing of technology
Slide 14: NeoStem Management & Senior Staff
14 Title: NeoStem Management & Senior StaffBody: Robin Smith, M.D., MBA, Chief Executive Officer and Chairman of the Board. Dr. Smith has acted as a senior advisor and investor to both publicly traded and privately held companies where she has played a significant role in restructuring and/or growin
Slide 15: Scientific Advisory Board
15 Title: Scientific Advisory Board Body: Wayne A. Marasco, M.D., Ph.D. Chairman Chairman of Scientific Advisory Board. Associate Professor-Department of Cancer and Immunology & AIDS at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. He is taking the l
Slide 16: Advisory Board
16 Title: Advisory BoardBody: Ron Rothenberg MD, FACEP Dr. Rothenberg is a Fellow of the American College of Emergency Physicians (FACEP) and is the founder of the California HealthSpan Institute in Encinitas, California. He was the 10th M.D. in the world to become fully board certified by the Ameri
Slide 17: Capitalization
Capitalization Shares Common Stock 4,318,168 Stock Options 1,060,800 Weighted average exercise price = $5.95 Warrants 2,084,938 Weighted average exercise price = $7.04 Fully Diluted Ownership 7,463,906 NBS Price Per Share $3.76 Market Capitalization $16.2 million Stock Symbol (AMEX) NBS Warrant Symb
Slide 18: Investor Considerations
18 Title: Investor ConsiderationsBody: Building product pipeline that would appeal to a large pharmaceutical companyAmgenBoston ScientificCelgeneGenzymeTevaPerkinElmer/Viacell ($300 million acquisition)Proprietary Technology Recurring revenue/inexpensive source of cash flowCreating a brand as a new
Slide 19: Questions
19 Title: QuestionsBody: Robin Smith, MD MBAChairman & CEODirect: (212) 584-4174Email: rsmith@neostem.com NeoStem, Inc.420 Lexington AvenueSuite 450New York, NY 10170Main: (212) 584-4180Fax: (646) 514-7787www.neostem.com 1.888.STEM BANK